11 research outputs found
In Search of Civic Virtue : On the Use of the Founders in Political Discourse
This essay examines three competing interpretations of the Founding Fathers that were made in the contested political climate of the 1980s. The first is Marc Plattner s neoclassical economic interpretation that stresses Madisonian principles of law, property rights, and the danger of majoritarian rule to justify a minimal rule-based government and free market capitalism. The second is Robert Bellah s communitariandemocratic interpretation, which appeals to the Founders and our republican traditions to critique excessive individualism and advance a more democratic politics governed by the norms of civic virtue. The third approach considered is the anti-Federalist critique of the Founders by Sheldon Wolin, who sees in the Constitution the beginnings of a system of national capitalism and state power that undermined localized and democratic political culture. Each approach will be assessed for its contribution toward a more participatory notion of public life
BRINGING THE ECONOMY BACK IN (AGAIN): CONCEPTIONS OF THE CAPITALIST STATE AND THEIR RELEVANCE FOR PUBLIC POLICY
This paper considers one of the central issues in contemporary political sociology--the question of the "autonomy" of the state--in the context of recent political and economic events in the U.S. A number of political theorists have challenged the dominance of what they see as an overly-deterministic conception of the state. They advocate "bringing the state back in" by emphasizing the independent influence of state structures, state manager, political parties, and "political" factors over other social and (especially) economic phenomena. Some of this work stressing the "primacy of the political" addresses the deficiencies of previous mainstream orientations in political science and political sociology--for example, pluralist conceptions, or structural functionalism (Cf. Skocpol, 1985:4-5). But most of it is directed toward the recent body of work on the state within the Marxist tradition--with varying degrees of sympathy
Mid-American Review of Sociology, Volume 6, Number 2 (WINTER, 1981): Book Review
Review of Werner Sombart's "Why is There no Socialism in the United States?
Recommended from our members
Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia.
PurposeStandard cytotoxic induction chemotherapy for acute myeloid leukemia (AML) results in prolonged neutropenia and risk of infection. Romyelocel-L is a universal, allogeneic myeloid progenitor cell product being studied to reduce infection during induction chemotherapy.Patients and methodsOne hundred sixty-three patients with de novo AML (age ≥ 55 years) receiving induction chemotherapy were randomly assigned on day 0 (d0), of whom 120 were evaluable. Subjects received either romyelocel-L infusion on d9 with granulocyte colony-stimulating factor (G-CSF) starting daily d14 (treatment group) or G-CSF daily alone on d14 (control) until absolute neutrophil count recovery to 500/µL. End points included days in febrile episode, microbiologically defined infections, clinically diagnosed infection, and days in hospital.ResultsMean days in febrile episode was shorter in the treatment arm from d15 through d28 (2.36 v 3.90; P = .02). Similarly, a trend toward decreased microbiologically defined infections and clinically diagnosed infection in the treatment arm was observed from d9 to d28 (35.6% v 47.5%; P = .09), reaching a statistically significant difference from d15 to d28 (6.8% v 27.9%; P = .002). Because of this, antibacterial or antifungal use for treatment of an infection was significantly less in the treatment group (d9-d28: 44.1% v 63.9%; P = .01). Significantly fewer patients in the treatment arm received empiric antifungals from d9 tod28 (42.4% v 63.9%; P = .02) and d15-d28 (42.4% v 62.3%; P = .02). Patients in the treatment arm also had 3.2 fewer hospital days compared with control (25.5 v 28.7; P = .001). Remission rates and days to absolute neutrophil count recovery were similar in the two groups. No patients in the romyelocel-L plus G-CSF group died because of infection compared with two patients in the control arm. No graft-versus-host disease was observed.ConclusionSubjects receiving romyelocel-L showed a decreased incidence of infections, antimicrobial use, and hospitalization, suggesting that romyelocel-L may provide a new option to reduce infections in patients with AML undergoing induction therapy
Utility of Single versus Tandem Autotransplants for Advanced Testes/Germ Cell Cancer: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis
Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia.
PURPOSE: Standard cytotoxic induction chemotherapy for acute myeloid leukemia (AML) results in prolonged neutropenia and risk of infection. Romyelocel-L is a universal, allogeneic myeloid progenitor cell product being studied to reduce infection during induction chemotherapy.
PATIENTS AND METHODS: One hundred sixty-three patients with de novo AML (age ≥ 55 years) receiving induction chemotherapy were randomly assigned on day 0 (d0), of whom 120 were evaluable. Subjects received either romyelocel-L infusion on d9 with granulocyte colony-stimulating factor (G-CSF) starting daily d14 (treatment group) or G-CSF daily alone on d14 (control) until absolute neutrophil count recovery to 500/µL. End points included days in febrile episode, microbiologically defined infections, clinically diagnosed infection, and days in hospital.
RESULTS: Mean days in febrile episode was shorter in the treatment arm from d15 through d28 (2.36
CONCLUSION: Subjects receiving romyelocel-L showed a decreased incidence of infections, antimicrobial use, and hospitalization, suggesting that romyelocel-L may provide a new option to reduce infections in patients with AML undergoing induction therapy